IL-17 in the prediction of the efficacy of biologic therapy for psoriasis
Abstract
Introduction . Psoriasis is a common chronic immune-mediated inflammatory skin disease that significantly reduces patients’ quality of life. Modern treatment approaches, especially biologic therapy, demonstrate high efficacy; however, there is substantial interpatient variability in treatment response. Aim . To develop a prognostic model for assessing the risk of biologic therapy failure in patients with psoriasis. Materials and methods . The study included 52 patients with moderate-to-severe psoriasis receiving IL-17A inhibitor therapy. A comprehensive analysis of clinical parameters (PASI, BSA) and serum cytokine levels was performed. Treatment efficacy was assessed after 3 months according to a 50% reduction in the PASI score. Results. A therapeutic response was achieved in 75% of patients. The key predictor of treatment efficacy was the IL-17 level: patients with a positive response had significantly higher baseline levels of this cytokine. Based on the obtained data, a mathematical model for predicting the efficacy of biologic therapy was developed (p < 0.001; AUC = 0.820; 95% CI: 0.670–0.969) with a sensitivity of 69.2% and specificity of 82.1%. Discussion . A significant association was found between baseline IL-17 levels and treatment response. High IL-17 concentrations indicate an active Th17 response and predict a better treatment outcome. The developed model makes it possible to personalize treatment selection and minimize the risk of ineffective therapy. Conclusions . IL-17 levels are a significant predictor of the efficacy of biologic therapy in psoriasis. The developed prognostic model has high diagnostic value. A personalized approach to therapy selection based on biomarkers can optimize psoriasis treatment. The study results provide a basis for the development of personalized medicine in dermatology.